MiMedx Group ($MDXG), the maker of regenerative biomaterials products, plans to launch AmnioFill, a placental collagen matrix designed to treat larger acute and chronic wounds found in surgical settings.
AmnioFill, which will begin distribution later this month, will be offered in a number of sizes and configurations to meet surgical needs, the company said.
By using its Purion Process to process human amniotic membranes, the company creates tissue implants. MiMedx acquires human placentas through a donor program for mothers delivering in full-term cesarean births. In 2014, it had sold more than 275,000 of its allografts for applications including wound care, surgical, sports medicine, ophthalmic and dental indications.
Parker H. "Pete" Petit, chairman and CEO, said in a statement: "We expect that AmnioFill will be an ideal solution for physicians in the treatment of dehisced surgical wounds and other deep complex and hard-to-heal surgical wounds that require a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue."
According to statistics cited by the company, there were 53 million outpatient procedures performed in the U.S. in 2010, and although there have been huge advances in preoperative care, the rate of surgical wound dehiscence has remained at about 1% to 3%. For example, the company said, breast reconstruction incisional dehiscence rates range from 10% to 15% in a setting with radiation therapy and abdominal wall surgical dehiscences have a mortality rate as high as 45%.